Evidence mapPaperPMID 41324519Full record

Trial reportJACC. Cardiovascular imaging2026

Statin Effects on Pericoronary Adipose Tissue Density in People With HIV: Insights From the REPRIEVE Trial.

Borek Foldyna, Ibrahim Hadzic, Thomas Mayrhofer, Júlia Karády, Jana Taron, Márton Kolossváry, Vineet K Raghu, Sara McCallum, Kayla Paradis, Marissa R Diggs and 16 more

Registry-linked trialAbstract readRandomized Controlled TrialMulticenter Study
In one paragraph

Trial report in JACC. Cardiovascular imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It reports registered trial NCT02344290. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02344290 phase3completed

Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE

Ran2015Enrolled7,769Registered outcomes37Posted comparisons40ConditionsCardiovascular Diseases, HIVArmsPitavastatin, Placebo
Open the trial in the graph
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors.

Borek FoldynaCardiovascular Imaging Research Center, Department of Radiology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA. Electronic address: bfoldyna@mgh.harvard.edu.
Ibrahim HadzicCardiovascular Imaging Research Center, Department of Radiology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.
Thomas MayrhoferCardiovascular Imaging Research Center, Department of Radiology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA; Center for Preventive Medicine and Digital Health, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.
Júlia KarádyCardiovascular Imaging Research Center, Department of Radiology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA; Department of Medicine, Boston Children's Hospital, Boston, Massachusetts, USA; Heart and Vascular Center, Semmelweis University, Budapest, Hungary.
Jana TaronCardiovascular Imaging Research Center, Department of Radiology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA; Department of Radiology, Medical Center, University of Freiburg, Faculty of Medicine, Freiburg, Germany.
Márton KolossváryCardiovascular Imaging Research Center, Department of Radiology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA; Metabolism Unit, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.
Vineet K RaghuCardiovascular Imaging Research Center, Department of Radiology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.
Sara McCallumMetabolism Unit, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.
Kayla ParadisCardiovascular Imaging Research Center, Department of Radiology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.
Marissa R DiggsMetabolism Unit, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.
Sarah M ChuMetabolism Unit, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.
Alex B LuMetabolism Unit, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.
Charurut SomboonwitUniversity of South Florida, Tampa, Florida, USA.
Jose I BernardinoHIV Unit, Internal Medicine Department, Hospital Universitario La Paz, IdiPAZ, Madrid, Spain.
Michael P DubéAIDS Healthcare Foundation and University of Southern California Keck School of Medicine, Los Angeles, California, USA.
Craig A SponsellerKowa Pharmaceuticals America, Montgomery, Alabama, USA.
Markella V ZanniMetabolism Unit, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.
Gerald S BloomfieldDepartment of Medicine, Duke Global Health Institute and Duke Clinical Research Institute, Duke University, Durham, North Carolina, USA.
Carlos D MalvestuttoDivision of Infectious Diseases, The Ohio State University Medical Center, Columbus, Ohio, USA.
Carl J FichtenbaumDivision of Infectious Diseases, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA.
Judith A AbergDivision of Infectious Diseases, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Judith S CurrierDivision of Infectious Diseases, David Geffen School of Medicine at the University of California, Los Angeles, Los Angeles, California, USA.
Heather J RibaudoCenter for Biostatistics in AIDS Research, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.
Pamela S DouglasDuke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina, USA.
Michael T LuCardiovascular Imaging Research Center, Department of Radiology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.
Steven K GrinspoonMetabolism Unit, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.

Funding

AIDS Clinical Trials Group for Research on Therapeutics for HIV and Related InfectionsUM1AI068636 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · 2021 to 2025
$229.0M
Statistical and Data Management Center (SDMC), AIDS Clinical Trials Group (ACTG)UM1AI068634 · NIAID · HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH · 2021 to 2025
$81.6M
AIDS Clinical Trial Group Laboratory CenterUM1AI106701 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · 2021 to 2025
$54.5M
1/2 REPRIEVE Extension for Trial CompletionUG3HL164285 · NHLBI · MASSACHUSETTS GENERAL HOSPITAL · 2023 to 2025
$9.5M
ROLE OF DIETARY CONSTITUENTS ON GENE EXPRESSION IN INTESTINAL EPITHELIUMP30DK040561 · MASSACHUSETTS GENERAL HOSPITAL · 1994 to 2025
$6.0M
2/2 REPRIEVE Extension for Trial CompletionU24HL164284 · NHLBI · MASSACHUSETTS GENERAL HOSPITAL · 2023 to 2025
$1.7M
Pericoronary adipose tissue density a novel CT-derived marker of local inflammation and coronary artery disease in people living with HIVR01HL170877 · MASSACHUSETTS GENERAL HOSPITAL · 2025 to 2025
$417k
Deep learning to assess cardiovascular disease risk from chest imagingK01HL168231 · MASSACHUSETTS GENERAL HOSPITAL · 2025 to 2025
$175k
NHLBI NIH HHS K01 HL168231NHLBI NIH HHS R01 HL170877NHLBI NIH HHS U01 HL123336NHLBI NIH HHS U01 HL123339NHLBI NIH HHS U24 HL164284NHLBI NIH HHS UG3 HL164285NIAID NIH HHS UM1 AI068634NIAID NIH HHS UM1 AI068636NIAID NIH HHS UM1 AI106701NIDDK NIH HHS P30 DK040561
6 · The paper itself

Abstract

backgroundThe effects of statin therapy on pericoronary adipose tissue (PCAT) and its relationship with plaque progression and outcomes in people with HIV (PWH) remain poorly understood.

objectivesThe aim of this study was to evaluate PCAT density changes over time; statin effects on PCAT; and associations among PCAT changes, coronary plaque, and clinical outcomes.

methodsIn the REPRIEVE (Randomized Trial to Prevent Vascular Events in HIV) mechanistic computed tomographic (CT) substudy (n = 753, mean age: 51 ± 6 years, 17% women), PCAT density was measured from noncontrast CT images at baseline and 2 years, while coronary plaque volumes (total, calcified, and noncalcified) were assessed from contrast-enhanced CT angiograms. Analyses were stratified by coronary artery disease burden (segment involvement score 0, 1-3, or ≥4) and adjusted for technical parameters, atherosclerotic cardiovascular disease risk, body mass index, inflammatory biomarkers, and statin allocation. Associations among PCAT, plaque changes, and events (all-cause mortality, major adverse cardiovascular events [MACE], and MACE or death) were evaluated.

resultsBaseline PCAT density was -87.7 ± 10.5 HU, increasing by 4.5 HU (95% CI: 3.8-5.2; P < 0.001) over 2 years. Pitavastatin prevented this increase in participants with segment involvement scores ≥4 (-1.7 HU vs +3.8 HU; P = 0.016, pitavastatin vs placebo, respectively). Greater PCAT density was associated with higher noncalcified plaque volume (per +10 HU, +5.0 mm

conclusionsPCAT density increases over time in PWH, but pitavastatin mitigates this in those with high coronary artery disease burden. PCAT density is associated with vulnerable plaque morphology and all-cause mortality, supporting its potential as a prognostic imaging biomarker in PWH. (Randomized Trial to Prevent Vascular Events in HIV [REPRIEVE]; NCT02344290).

Indexed as

Adipose TissueAdiposityComputed Tomography AngiographyCoronary Artery DiseaseCoronary VesselsDyslipidemiasHIV InfectionsHydroxymethylglutaryl-CoA Reductase InhibitorsAdultCoronary AngiographyDisease ProgressionEpicardial Adipose TissueFemaleHumansMaleMiddle AgedHydroxymethylglutaryl-CoA Reductase Inhibitorscoronary artery diseasecoronary plaquemajor adverse cardiovascular eventspeople with HIV

Identifiers

PMID41324519
PMCPMC12766717

What Socratic holds

Texttitle and abstract
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.